Stocks of Medtronic Plc (NYSE:MDT) traded higher last session on Wall Street, up 1.11% to $94.06.
MDT stock price is now 7.60% away from the 50-day moving average and 9.94% away from the 200-day moving average. The market capitalization of the company currently stands at $120.64B.
With the price target enhanced from $92 to $107, Citigroup Upgraded its rating from Neutral to Buy for Medtronic Plc (NYSE: MDT). On October 10, 2024, RBC Capital Mkts Upgraded its previous ‘Sector Perform’ rating to ‘Outperform’ on the stock increasing its target price from $98 to quote $105, while ‘Oppenheimer’ rates the stock as ‘Perform’
In other news, Wall Brett A., EVP & Pres Neuroscience sold 12,437 shares of the company’s stock on Jan 24 ’25. The stock was sold for $1,119,330 at an average price of $90.00. Upon completion of the transaction, the EVP & Pres Neuroscience now directly owns 40,979 shares in the company, valued at $3.85 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jan 24 ’25, Officer Wall Brett A. bought 12,437 shares of the business’s stock. A total of $1,119,330 was incurred on buying the stock at an average price of $90.00. A total of 0.12% of the company’s stock is owned by insiders.
During the past 12 months, Medtronic Plc has had a low of $75.96 and a high of $95.57. As of last week, the company has a debt-to-equity ratio of 0.54, a current ratio of 1.90, and a quick ratio of 1.43.
The net profit margin was 12.83% and return on equity was 8.42% for MDT. The company reported revenue of $8.29 billion for the quarter, compared to $8.09 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 2.51 percent.
